Posts for Ticker ‘SVNT’

Top Day Trader Alerts (ACOR, AVNR, INFY, SVNT, SPPI, TSM)

These are this Friday morning’s top day trader and active trader alert stocks.  We have provided a link through to VSInvestor.com with more detailed price and volume analysis on each stock below:

Acorda Therapeutics, Inc. (NASDAQ: ACOR) down on FDA link that made its data public.

AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) is the top gainer so far as Zenvia data showed positive results at higher doses.

Infosys Technologies Limited (NASDAQ: INFY) beat earnings, but shares are down about 3%.

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) is trading up over 4% after a secondary offering, and an upgrade probably helped here.

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) is down sharply on complete response letter from FDA for FUSILEV in advanced metastatic colorectal cancer going against it.

Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE: TSM) is up marginally on over 1 million shares a sales drop still met plan.

You can join our open email distribution list to get updates each morning on analyst upgrades and downgrades, top day trader alerts, IPO’s and secondary offerings, Warren Buffett and other guru activity, M&A and more.

JON C. OGG
October 9, 2009

More Secondaries Hitting the Market (LAD, PZG, SVNT, GOL)

Money Stack ImageWe have seen at least four different secondary offerings this morning, and there are some others that are pending to be priced for trading today.  The offerings are from Lithia Motors Inc. (NYSE: LAD), Paramount Gold & Silver (AMEX: PZG), Savient Pharmaceuticals (NASDAQ: SVNT), and GOL Linhas Aereas Inteligentes SA (NYSE: GOL).  Details on pricing and reactions are available below.
Read More »

Top Analyst Upgrades (AKS, BMY, CREE, JPM, LRCX, MAR, RIMM, SVNT, SE, VIA)

These are this Friday morning’s top Wall Street analyst upgrades and positive research calls:

AK Steel (AKS) Raised to Buy at Deutsche Bank.
Bristol-Myers (BMY) Started as Outperform at Wells Fargo.
Cree (CREE) Started as Overweight at JPMorgan
J.P. Morgan (JPM) Started as Strong Buy at Raymond James.
Lam Research (LRCX) Raised to Outperform at Credit Suisse.
Marriott (MAR) Raised to buy at BofA/Merrill Lynch.
Research in Motion (RIMM) Raised to Outperform at R.W. Baird.
Savient Pharma (SVNT) Raised to Outperformat Oppenheimer.
Spectra Energy (SE) Raised to Conviction Buy List at Goldman Sachs.
Viacom (VIA) Raised to Overweight at Piper Jaffray.

You can join our open email distribution list to get updates each morning on analyst upgrades and downgrades, top day trader alerts, IPO’s and secondary offerings, Warren Buffett and other guru activity, M&A and more.

JON C. OGG
October 9, 2009

Top 10 Analyst Upgrades and Downgrades (ABX, BGFV, DLR, DISH, HOLX, HGSI, MYGN, PMC, SVNT, TLB)

These are ten of the top pre-market early analyst upgrades, downgrades, and initiations we have seen from Wall Street early this Tuesday morning:

Barrick Gold (ABX) Cut to Sector Perform at CIBC.
Big 5 Sports (BGFV) Raised to Neutral from Underweight at Piper Jaffray.
Digital Realty Trust (DLR) Cut to Hold at KeyBanc.
DISH Network (DISH) Raised to Outperform at CRedit Suisse.
Hologic (HOLX) Cut to Hold at Citigroup.
Human Genome (HGSI) Raised to Buy at ThinkEquity.
Myriad Genetics (MYGN) Started as Outperform at William Blair.
Pharmerica (PMC) Cut to Perform at Oppenheimer.
Savient Pharma (SVNT) Cut to Underperform at Jefferies.
Talbots (TLB) Raised to Outperform at FBR.

JON C. OGG
AUGUST 4, 2009

Top Day Trader Alerts (SVNT, HURN, RPRX, EBAY, HUM, ONTY)

The following are among the top day trader and active trader alert stocks with major price and volume action.  We have links to more detailed analysis and price action at VSInvestor.com:

Savient Pharmaceuticals (NASDAQ: SVNT) is among the worst performers on disappointing FDA action on its gout treatment.

Huron Consulting Group Inc. (NASDAQ: HURN) is the worst performer on earnings restatements and management being replaced.

Repros Therapeutics (NASDAQ: RPRX) is down sharply by over 50% after stopping trials on patient safety.

eBay Inc. (NASDAQ: EBAY) is up over 4% after getting the barron’s cover story.

Humana Inc. (NYSE: HUM) is up over 4% on higher earnings growth.

Oncothyreon Inc. (NASDAQ: ONTY) is up big on lung cancer study data.

The 24/7 Wall St. Team

Top Analyst Upgrades (APA, BIDU, BHP, STD, BK, CENT, IVZ, QCOM, SVNT, STT, TXN)

These are the top analyst upgrades and positive research calls from Wall Street we have seen early this Wednesday morning with more than two hours until the market opens:

Apache (APA) Raised to Strong Buy at S&P.
Baidu (BIDU) Target Raised to $350 at Goldman Sachs.
BHP Billiton (BHP) Raised to Outperform at Macquarie.
Banco Santander (STD) Raised to Buy at BofA/Merrill.
Bank of New York Mellon (BK) Started as Buy at SunTrust Robinson Humphrey.
Central Garden (CENT) Raised to Buy at SunTrust Robinson Humphrey.
Invesco (IVZ) Raised to Strong Buy at S&P.
QUALCOMM (QCOM) Raised to Buy at Goldman Sachs.
Savient Pharmaceuticals (SVNT) Raised to Perform at Oppenheimer.
State Street (STT) Started as Buy at SunTrust Robinson Humphrey.
Texas Instruments (TXN) Raised to Buy at BofA/Merrill.

JON C. OGG

Shares of Savient Pharmaceuticals Inc. Soar Despite FDA Concern Over Drug Safety (SVNT)

underShares of Savient Pharmaceuticals Inc. (Nasdaq: SVNT) climbed on Friday after an announcement by the FDA that the company’s drug Krystexxa appears to successfully treat gout, despite evidence of potentially deadly side effects. Read More »

Savient (SVNT) Rises 55% On Bad News

bearShares in pharma firm Savient (SVNT) are up 55% to $9.13 on what would appear to be very bad news. The FDA issued a statement saying it has safety concerns about the company’s gout drug.

According to the agency, side effects of the drug Krystexxa include sudden death from heart attack and allergic reactions. The silver lining is that the treatment may actually be approved. The FDA commented that it does “does not dispute the efficacy” of the drug. Read More »

The 52-Week Low Club (CCC)(MTL)(ARM)(TSN)(SVNT)

Sad_clown_2Calgon Carbon (CCC) Outstanding notes convert to common shares. Drives stock to $10.54 from 52-week high of $23.03.

Mechel (MTL) Russian coal miner may issue up to 138.8 million preferred shares. Dives to $3.77 from 52-week high of $58.66.

Arvinmeritor (ARM) JPMorgan cuts rating for auto suppliers. Falls to $4.54 from 52-week high of $18.11.

Tyson Foods (TSN) Stephens research analyst lowers earnings forecast. Drops to $8.14 from 52-week high of $19.50.

Savient Pharmaceuticals (SVNT) Plummets on safety concerns about one if its treatments and analyst downgrade. Sells off to $2.80 from 52-week high of $28.42.

Douglas A. McIntyre

Savient: Jim Cramer’s Old Favorite Biotech Implodes (SVNT)

Savient_logoSavient Pharmaceuticals Inc. (NASDAQ: SVNT) is feeling the wrath of the trading gods today.  Shares are down some 74% at $2.95 in close to 10-times normal trading volume.  The culprit for today’s biotech implosion is the safety profile of its key gout drug candidate Puricase in additional Phase III study data.  Interestingly enough, the drug does appear to work.  One reason this has so many followers is because Jim Cramer called this one his #1 Speculative Stock last year.  With so few new gout treatment alternatives, this news and this stock is worth a look.

Read More »

Top Pre-Market Analyst Downgrades (BIIB, CBEY, EHTH, NT, OSK, PAET, RYAAY, SVNT)

These are some of the key analyst downgrades and negative analyst calls we have seen early this Monday morning with over 2 hours to open:

  • Biogen Idec (BIIB) Cut to Sell at Banc of America.
  • Cbeyond Communications (CBEY) Cut to Sell at Citigroup.
  • EHealth (EHTH) Cut to Market Perform at JMP Securities.
  • Nortel (NT) Cut to Hold at Jefferies.
  • Oshkosh (OSK) Cut to Neutral at Credit Suisse.
  • PAETEC (PAET) Cut to Market Perform at Wachovia; Cut to Sell at Citigroup..
  • Ryanair (RYAAY) Cut to Underperform at Credit Suisse.
  • Savient Pharma (SVNT) Cut to Hold at Jefferies.

Jon C. Ogg
August 4, 2008

George Soros Top Equity Holdings (AAPL, AUXL, BFLY, CBI, CMG, CRUS, COV, MAPP, POT, SVNT)

This week we got to see critical SEC filings showing holdings of many key and influential investors.  Included in these filings were billionaire George Soros, a billionaire whom is loved by some and much less ‘well thought of’ by others over his currency trading history of over his MoveOn.org attempts.  Either way, investors still watch Soros.  These are the holdings of Soros Fund Management LLC as of December 31, 2007.  These were listed as the top holdings and are not at all his entire positions.  Soros Fund Management LLC was listed as having some $2.269 Billion in the total filing, and these positions here only equate to $360+ million, so there are many more positions.  As with all of these holdings, these positions may have changed or been eliminated as of the dates noted.  Here is a summary of his larger positions with a dollar amount provided by Soros as filer and a share count:

  • Apple Inc. (NASDAQ: AAPL)   $32,000,000;  161,550 shares
  • Auxilium Pharma (NASDAQ: AUXL)   $36,473,000;  1,216,180 shares
  • Bluefly Inc. (NASDAQ: BFLY)   $36,451,000;  48,601,156 shares… an old favorite of his…
  • Chicago Bridge & Iron Co. (NYSE: CBI)   $29,743,000;  492,100 shares
  • Chipotle Mexican Grill, Inc. (NYSE: CMG)  $32,404,000;  220,332 shares
  • Cirrus Logic Inc. (NASDAQ: CRUS)   $24,376,000;  4,616,666 shares
  • Covidien, Ltd. (NYSE: COV)   $32,194,000;  726,900 shares
  • MAP Pharmaceuticals (NASDAQ: MAPP)   $71,374,000;  4,076,169
  • Potash Corp. (NYSE: POT)   $37,933,000;  263,500 shares
  • Savient Pharmaceuticals (NASDAQ: SVNT)   $25,002,000;  1,088,461 shares

As Soros himself says …."Contrary to the tenets of market fundamentalism, financial markets do not tend towards equilibrium; they are crisis prone."   

Other billionaires and their holdings filed this week:
Bill Gates
Carl Icahn
Warren Buffett

Jon C. Ogg
February 16, 2008

Cramer Reviews 2007 Into 2008 (AUY, ABX, BMRN, HAL, AAPL, MO, SVNT, RIMM, GOOG, AMZN, RAD, LVLT, NYX, CSCO)

On tonight’s MAD MONEY on CNBC, Jim Cramer kicked off 2008 by being somewhat cautious on the volatility in 2008.  Cramer said he wants to Add gold to the portfolio  with Barrick Gold (NYSE: ABX) for speculative gold and Yamana (NYSE:AUY) growth gold.  Cramer did review TOP 9 PICKS FOR 2007 and showed that if you contain your losses you can make money since the 9 picks he said were up 16% collectively.  He wants to contain losses and let the winners win:

  • Apple (NASDAQ:AAPL) is one he wants to stick with.  Halliburton (NYSE:HAL) is another one he wants to stick with as well as it underperformed the sector.  Altria (NYSE:MO) beat the averages and he likes the management there.
  • Rite Aid (NYSE:RAD) was a horrible loser with -53% and Level 3 Communications (NASDAQ:LVLT) was down by -49%, but they did both rise substantially before rising.  Both had bad balance sheets and that was an omen he won’t try to repeat.Goldman Sachs (NYSE:GS) as a company only rose 8% because of the financial stocks, despite that it won in the entire group.  NYSE Euronext (NYSE: NYX) was the worst one with a horrible loss.  Cheap technology companies don’t work and that ended up being the case with Cisco Systems (NASDAQ: CSCO). 
  • Cramer said that the market is just too fickle to make year-end predictions in companies.  So with an election and a crazy market he is not going to play that game.

Cramer did say that BIOTECH is the sector to speculate in during 2008, although he notes that with large rewards you can expect large risk.  He noted that his pick of Savient (NASDAQ:SVNT) and then the trade out into BioMarin (NASDAQ:BMRN) turned more than a 70% gainer there.

If you want to see our consolidated summary with our top Cramer coverage with all of his various lists of 2007 stocks that are being updated in the coming days you can see that here.  This morning he said that he sees agriculture and solar continuing to win, and his best sector for 2008 was just listed as oil & gas.  He also said he wouldn’t be a seller of Apple (NASDAQ:AAPL) because of the 30% earnings growth that only a handful of companies have; he’s still positive on three of his Four Horsemen of Tech Research-in-Motion (NASDAQ:RIMM) and Google (NASDAQ:GOOG), although he’d sell Amazon.com (NASDAQ:AMZN) above $100.00.

Jon C. Ogg
January 2, 2008

Savient’s New Gout Treatment Hits Targets (SVNT)

Savient Pharmaceuticals Inc. (NASDAQ: SVNT) is seeing its shares surging in pre-market trading.  The company showed statistically significant positive results for the Puricase Phase III study in treatment-failure of gout patients. Puricase’s 8mg dosage administered by a two-hour intravenous infusion every two weeks or every four weeks met Savient’s primary efficacy endpoint.

Savient also said it plans to file for approval with the FDA in 2008 based on the positive results from these Phase III trials.  If you will recall, this was Jim Cramer’s #1 SPECULATIVE STOCK FOR 2007

Shares closed yesterday at $14.46, and the 52-week trading range had been $10.58 to $15.75.  It now looks like it is trading at a new all-time high of $20.95 in pre-market activity.

Jon C. Ogg
December 13, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Cramer’s 2007 Picks Vs. The Markets To-Date (AAPL, NYX, CSCO, HAL, GS, MO, SVNT, RAD, LVLT)

Some people love Jim Cramer, and some people just love to bash him.  Some try to run percentage gains that he would be up or down at any given moment.  Some revere him, and some love to show where his picks underperform on a broad market.  So what we decided to do was see how the TOP 9 CRAMER PICKS FOR 2007 performed versus the overall stock market.

We took issue with the last Barron’s article that was noting an underperformance.  James Altucher of TheStreet.com also took issue with a measurement of Cramer picks as well.  What investors around the block and in all walks need to consider is that once again these issues aren’t really relevant.  Some people make many following Cramer and some people have made money shorting some of his picks.  The truth is that unless you had a black box trading program that traded and tracks every single pick of his and that followed an exact set of rules, then this is just for conversation.  It is really impossible to make calculations when you consider all of the caveats and that all entry points are rough guestimates or theoretical based on a snapshot.

So what we decided to do was run CRAMER’S TOP 9 PICKS FOR 2007 where Cramer made these picks for the entire year.  These are based upon a snapshot in time with all equal dates of DEC 29, 2007 even though he made the picks in the days right after the 2007 start.  We have also outlined what Cramer said about each one of these picks (hyperlink on names) at the start of the year so you can compare the world of early-January to today.  Here is how the Cramer picks did, but keep in mind this excludes dividends and other restructure payouts:

Cramer’s 2007 Picks Versus The Markets               

Speculative Picks:        DEC-31   SEP-04    Up/Down   Percent

  • Level 3     LVLT    $5.60        $5.31     ($0.29)     -5.17%
  • Rite Aid    RAD     $5.44        $5.11     ($0.33)     -6.06%
  • Savient    SVNT    $11.21     $13.35     $2.14     19.09%

Growth Picks:                  DEC-31   SEP-04   Up/Down  Percent               

  • NYSE        NYX     $96.88    $73.84    ($23.04)    -23.78%
  • Apple        AAPL   $84.84    $144.16   $59.32      69.89%
  • Cisco      CSCO   $27.33    $32.32     $4.99        18.25%

Value Picks:                               DEC-31   SEP-04    Up/Down    Percent            

  • Altria                      MO    $63.14     $69.67     $6.53      10.34%
  • Goldman Sachs GS    $198.34   $180.80  ($17.54)  -8.84%
  • Halliburton         HAL    $30.81     $34.99     $4.18      13.56%   

THE MARKETS:        DEC-31       SEP-04        GAIN   Percent

  • DJIA             12,463.15   13,448.86     985.71    7.90%
  • NASDAQ       2,415.29     2,630.24      214.95    8.89%
  • S&P500        1,418.30     1,489.42       71.12      5.01%

Out of the Cramer Picks for 2007, 5 of the 9 picks landed in positive territory as of the close.  The results are skewed a bit because of the huge performance of Apple (AAPL). But we decided to smooth that out too. On a simple basis and excluding dividends, it looks like the Cramer portfolio has an average of 9.68% return year to date (once again, this excludes dividends).  If you remove Apple’s huge gains, you get a 2.17% gain (outside of dividends) and if you use the ‘remove best and worst single choices’ which also kicks out the large drop in NYSE (NYX) shares then you get a gain of 5.88% (outside of dividends).

The truth is that numbers can be manipulated because they are based upon a snapshot in time and many models do not adequately account for restructuring, splits, spin-offs, and reorganizations.  This is at least a start now that we are 2/3 of the way through 2007. 

Jon C. Ogg
September 4, 2007

If these didn’t align properly it was because of a formatting issue, and we apologize for any misaligned numbers.

Cramer & Mad Money Host The 500th Show (Major 2007 Highlights)

Stock Tickers: AAPL, YHOO, EBAY, LVLT, DNDN, NYX, AMZN, FWLT, GOOG,DELL, MSFT, INTC, C, RAD, SVNT, CSCO, MO, GS, HAL, DNDN

On tonight’s MAD MONEY on CNBC, Jim Cramer featured his 500th show on the air.  He noted that there is not a need to go over 600 stocks in a year as much as there is to bring you methodologies and a thought process. Cramer said he was going to review some of his blunders since the show began, but we wanted to show some of the key calls with some real longevity that he has made this year that are not just one-time calls here and there.  These are not the calls that Cramer discussed on his show tonight, but these are actually the big calls he’s made for longer-term in individual stocks that are still pertinent and active.

Cramer’s TOP 9 PICKS FOR 2007……..

Cramer’s "NEW FOUR HORSEMEN OF TECHNOLOGY," plus some second tier technology picks.

Cramer’s Apple (AAPL) strategy ahead of the iPhone release.

Will eBay (EBAY) & Yahoo! (YHOO) Merge, as Cramer hopes.

Cramer has four groups for a wildly bullish stock market, and he’s got oil and gas plays for the same wildly bullish market.

He’s still sticking with Google (GOOG)….Did he say $1,000 or $600?  He’s even backing Dell (DELL) after Michael Dell returned.

Cramer even gave a bunch of near and long-term targets on each DJIA component for the year.

Cramer still wants Semel out of Yahoo! (YHOO) and wants Chuck Prince out of Citigroup (C), just like we do.

He even gave some methodologies for the next Dendreon (DNDN).

Jon C. Ogg
June 11, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.